Targeting HCV protease
The HCV NS3/4 serine protease is an excellent target for novel therapies, with clinical trials of several compounds underway.
Phase I studies of SCH 503034, as monotherapy and in combination with peg-IFN-α2b, were reported. In a double-blind study, 61 patients with refractory genotype 1 chronic hepatitis C were treated with rising doses of SCH 503034, 100 mg twice daily to 400 mg oral capsules three times daily, or placebo, for 14 days (abstract 94). Mean maximum reduction in viral load with SCH 503034 400 mg three times daily was 2.06 log 10 from baseline, with accompanying improvements in liver function tests. SCH 503034 was well tolerated, with a similar adverse event profile to that of placebo.
In an open-label, Phase I study, again in HCV genotype 1 infected non-responders to peg-IFN-based therapy, a mean maximum reduction in viral load of 2.9 log 10 was reported with SCH 503034 400 mg three times daily and peg-IFN-α2b 1.5 µg/kg weekly for 14 days, compared with 1.1 log for peg-IFN alone (abstract 201). In 4 out of 10 patients taking SCH 503034 400 mg three times daily and peg-IFN-α2b, viral load reached undetectable levels during treatment, compared with none of the 22 patients receiving peg-IFN alone. Combination treatment was well tolerated with a similar adverse event profile to that of peg-IFN alone, except for a slight increase in headache.
A large, randomized Phase II dose-finding study of SCH 503034 in combination with peg-IFN-α2b, with or without RBV, is now underway in 300 patients with chronic hepatitis C worldwide. Extrapolation of 14-day viral load data from the Phase I trial, using a simple modification of the viral dynamics model of Powers et al. [1] , predicts that combination therapy with SCH 503034 400mg three times daily and peg-IFN will result in effective reduction in HCV RNA for all patients at 12 weeks, with the majority predicted to be undetectable at week 8 (abstract 1266). If this is indeed found to be the case in subsequent trials, the viral dynamics model may prove useful in other settings to predict efficacy from very early viral load data.
Results of studies on three other protease inhibitors -VX 950 and ITMN A and B -were also presented.
Henk Reesink, from the Academic Medical Centre in Amsterdam, Netherlands, reported results of a Phase I dose-ranging study of VX-950 in genotype 1 infected patients with chronic hepatitis C (abstract 96). All patients dosed with an oral suspension of VX-950 450 or 750 mg three times daily or 1,250 mg twice daily forIntroduction and studies of VX-950, in combination with peg-IFN, are underway.
The challenge of mutations
A study aimed at characterizing the viral variants in the HCV NS3 protease domain of genotype 1 infected patients that were selected during 14 days of dosing with VX-950 demonstrated distinct patterns of mutations, including mutations at amino acid 156 and at three additional positions in NS3 (abstract LB06). These could be linked to persistence or nonpersistence of the initial reduction in HCV RNA with treatment.
The fact that such mutations arise in response to different levels of drug pressure is not surprising, but it is to be hoped that by identifying optimal drug levels and/or combinations of the new protease inhibitors (PIs), antiviral efficacy can be maintained. For example, it has already been shown that two further PIs, ITMN A and B, still in the pre-clinical stages of development, retain their potency against the mutation at amino acid 156 in NS3 seen following VX-950 treatment (abstract 869). The two compounds also showed potency against primary resistance mutations to the PI, BILN-2061, the development of which has been stopped due to cardiac toxicity in monkeys.
Originally developed as an immunomodulator to directly inhibit the anti-inflammatory cytokine interleukin-10, ammonium trichlorotellurate (AS101) has also been shown to inhibit HCV replication via HCV NS3 serine protease. Michal Shalita-Chesner, from Rabin Medical Center, Petach Tikva, Israel, and coworkers demonstrated dose-dependent inhibition of NS3 serine protease catalysis in a fluorimetric assay, and inhibition of HCV replication in a sub-genomic Huh-7 replicon system (abstract 870).
Progress with polymerase inhibitors
The most advanced HCV polymerase inhibitor is valopicitabine (NM 283), an oral once-daily agent that blocks HCV RNA polymerase (abstract 95). Christopher O'Brien, from the Center for Liver Diseases, at the University of Miami, USA, presented interim results from a Phase IIb dose-ranging study of valopicitabine and peg-IFN-α2a in HCV genotype 1 infected non-responders to previous standard treatment.
At 12 weeks, 63% of patients treated with valopicitabine 800 mg and peg-IFN achieved an early viral response (EVR; greater than 2 log 10 reduction in viral load), compared with 41% of those treated with peg-IFN and RBV. Phase III clinical trials are planned for 2006.
Also under evaluation as a polymerase inhibitor is the nucleoside analogue R1479, which has shown high selectivity for HCV replication in cell culture (abstract 1170).
A role for host factors?
Various other avenues of research are also being explored. Drugs that target host factors required in the HCV lifecycle could be used as complimentary treatment to viral protease and polymerase inhibitors. Cyclophilins are cellular factors that facilitate protein conformation, and at least one of these, cyclophilin B, is known to interact with HCV polymerase NS5B to stimulate its RNA-binding activity, and hence to aid HCV replication [2] . The immunosuppressant drug cyclosporin A inhibits HCV replication via an action on cyclophilins, and its anti-HCV effect has also been demonstrated clinically. At the AASLD meeting, Scot Henry and colleagues from Erasmus Medical Centre, in Rotterdam, Netherlands, showed that the combination of cyclosporin A and mycophenolic acid acts synergistically and with distinct antiviral kinetics to inhibit HCV replication by up to 90% at higher doses (abstract 865). The group proposed that the combination may be a preferable immunosuppressive therapy to steroids in transplant patients, when re-infection of the graft is a concern.
NIM811 is a cyclosporin analogue that binds to cyclophilins with similar affinity to cyclosporin, but does not have its immunosuppressant effects (abstract 866). Kai Lin and colleagues from the Novartis Institute of Biomedical Research at Cambridge, Massachusetts, reported 3 log 10 reductions in HCV RNA levels with low doses of NIM811, and the compound showed equally potent activity in HCV replicons that were highly resistant to viral protease or polymerase inhibitors.
The interaction between the E2 envelope protein and the host CD81 cell is the target for the novel HCVentry-inhibiting peptide GNS 037, and early pre-clinical data suggest good potency, without any detectable peptide-induced cytotoxicity (abstract 98).
Another host target that could be useful for inhibiting HCV replication appears to be sphingolipid biosynthesis. In cell culture, the lipophilic long-chain base compound NA255, derived from a secondary fungal metabolite, has been shown to suppress HCV replicon replication in a dose-dependent manner (abstract 863). The mechanism of action appears to be by preventing host cell biosynthesis of sphingolipids, which are major components of lipid rafts, thereby inhibiting serine palmitoyltransferase and disrupting association of HCV non-structural proteins on the lipid rafts. Further investigation has isolated a sphingolipid-binding domain in the HCV NS5B protein, and it is suggested that interaction between NS5B and sphingolipids could be involved in HCV replicon replication. Sphingolipid inhibition by NA255 appears to have had no effect on host cell viability or cell cycle progression.
Modulators of the immune system
Stimulating the immune system to mount a response sufficient to achieve sustained HCV clearance is another interesting option, and considerable progress was reported at the AASLD meeting in the development of immune modulators acting via Toll-likereceptor 9 (TLR9). At least 10 different types of TLR are expressed on immune cells, and respond to microbial invasion by initiating inflammatory responses through induction of antimicrobial genes and proinflammatory cytokines and chemokines.
TLR9 is expressed on plasmacytoid dendritic cells (pDC), also known as natural IFN-producing cells. Stimulation of TLR9 leads to secretion of IFN-α and IFN-β, and activation of the cellular components of innate and adaptive immune responses needed for HCV control, notably T cells, natural killer (NK) cells, pDC and B cells.
John McHutchison, from Duke University, Durham, and colleagues reported promising results with the TLR9 agonist actilon (CPG10101), in Phase I studies with healthy volunteers and patients with chronic hepatitis C treated for 4 weeks. In one study, doserelated increases in IP-10 and IFN-α levels were reported, and these were associated with HCV RNA reductions ≥1 log in genotype 1 infected patients who had relapsed or were intolerant to peg-IFN and RBV therapy (abstract 131). Reductions in HCV RNA were seen within 24 hours of the first dose of treatment.
In a second, larger study of 48 healthy volunteers and 60 patients with chronic hepatitis C, actilon treatment was associated with activation of peripheral T cells, NK cells and monocytes in a dose-dependent manner, within 24 hours of the first dose (abstract 873). Cellular activation was spontaneously reversible within 3-5 days, suggesting that treatment does not induce uncontrolled immune or inflammatory responses. Larger studies of actilon, over longer periods of time, and in combination with peg-IFN and RBV are underway.
Reduction in HCV RNA levels has previously been reported with intravenous infusion of the TLR7 agonist isatoribine, but poor absorption of oral doses has led to the development of the prodrug ANA975. Results of a single oral dose, healthy volunteer study, reported at the meeting, showed efficient conversion of ANA975 to isatoribine at levels in plasma that were previously shown to reduce HCV RNA (abstract 858).
Interferon as a treatment platform
The most promising of the novel approaches to HCV treatment are moving into Phase II and III studies of combination treatment, usually with peg-IFN as the platform for therapy. However, approaches to the use of this gold-standard basis of HCV treatment have not stood still, and regimens are being tailored increasingly to the genotype of the infecting virus, and to the patient's own characteristics.
African-American/Caribbean ethnic grouping and obesity are two of the patient characteristics that are known adversely to affect response to HCV treatment. In a study comparing peg-IFN response rates in African-American and Caucasian HCV genotype 1 infected patients, the former were twice as likely to have breakthrough responses between weeks 24 and 48 of treatment (abstract 199). At baseline, they had higher mean body mass index and lower mean alanine aminotransferase, neutrophil and haemoglobin levels, and they were more likely to have hypertension or diabetes -any or all of which may have contributed to the poorer treatment responses.
The value of weight-based dosing of peg-IFN-α2b in overweight patients was demonstrated in a study of over 2,000 HCV patients, which showed an overall sustained virological response (SVR) of 66%, across all weight groups from 40 kg to over 85 kg (abstract 1256). Weight-based RBV treatment (800-1,400 mg/day) has also been associated with higher SVR rates across all weight groups compared with flat dosing (800 mg/day; abstract LB03). However, weight-based dosing of RBV was not found to have advantages over flat dosing in patients undergoing HCV re-treatment following relapse (abstract 59).
Optimal therapy in patients who failed prior therapy with standard peg-IFN and RBV-based regimens remains to be established, with only 10-12% of patients likely to achieve an SVR with re-treatment. Two options presented at the conference -doubling the dose of a weight based regimen or using a high fixed dose peg-IFN/RBV regimen -have met with some success. An SVR of 17% was achieved with peg-IFNα2b 3 µg/kg for 48 weeks compared with 12% with a dose of 1.5 µg/kg and, in contrast to the standard dosing regimen, African-American patients and those with F3/4 fibrosis did not have inferior SVR rates when treated with the high-dose regimen (abstract 60).
Week 12 data were available from the study of high fixed dose peg-IFN-α2a 360 µg/week for 12 weeks, followed by 180 µg/week, for up to 60 weeks, compared with standard dosing (180 µg/week, for up to 72 weeks; abstract LB04). A higher proportion of those treated with the high dose induction regimen cleared HCV RNA or achieved a ≥2log 10 reduction. 
Predicting IFN response
Growing evidence shows that it is possible to predict response to treatment, even earlier than the 12 week EVR level that is currently used to predict SVR, and hence to tailor duration of HCV treatment.
Two studies showed the value of rapid virological response (RVR) -HCV RNA <50 IU/ml after 4 weeks -in HCV genotype 1 infected patients. Donald Jensen, from Rush University Medical Center, Chicago, and colleagues reported that 20% of 729 genotype 1 infected patients treated with peg-IFN-α2a and RBV achieved an RVR (abstract 1155). Of these, about 90% achieved an SVR, whether they had HCV treatment for 24 or 48 weeks. In contrast, of those without an RVR at 4 weeks, less than 25% achieved an SVR with 24 weeks treatment, and under half achieved an SVR with 48 weeks treatment.
Preliminary data from another large study in HCV genotype 1 infected patients, from Peter Ferenci, from the University of Vienna, and co-workers comparing 24, 48 and 72 weeks of peg-IFN-based HCV treatment, depending on RVR and EVR, support the idea of a population of 'super-responders' (abstract 56). Amongst those who were assigned 24 weeks treatment, based on their RVR, there was an SVR of 66%. Further data are awaited on those who did not achieve an RVR and had longer courses of treatment.
However, a word of caution comes from Angelo Andriulli from CSS Hospital, San Giovanni Rotondo, Italy, and co-workers whose early work demonstrating the predictive value of RVR in patients infected with HCV genotype 2 or 3 underpins much of the more recent research in genotype 1 patients. With pooled data from Italian and Norwegian cohorts with a total of 403 patients, they have now shown that patients with severe fibrosis are least likely to achieve an RVR and, even when RVR is achieved in this group, relapse is common, so that patients do not achieve SVR (abstract 849). Thus, short treatment duration may not be appropriate for patients with chronic hepatitis C and severe fibrosis, even if they achieve an RVR.
Other IFNs
Two other novel approaches to IFN therapy were reported at the meeting. The addition of IFN-γ to consensus IFN, with or without RBV, for 48 weeks resulted in undetectable HCV RNA in up to 71% HCV genotype 1 infected patients, leading Stephan Kaiser, from the University Hospital of Tuebingen, Germany, and colleagues to suggest that IFN-γ may be an effective supplement or additive to IFN and RBV in difficult to treat genotype 1/high viral load patients, or those who do not tolerate RBV (abstract 203).
Promising results were also reported with the Albuferon -a novel recombinant protein consisting of IFN-α genetically fused to human serum albumin to prolong its activity -in previous non responders to IFN-α (abstract 204).
News of amantadine
The value of adding amantadine to peg-IFN and RBV is the subject of continuing debate and study. Patients who do not benefit from the additional treatment may have mutations in the HCV-p7 protein, which is involved in formation of transmembrane ion channels, the function of which has been shown to be blocked by amantadine. Ulrike Mihm, from Universitätsklinikum des Saarlandes, Homburg/Saar, Germany, and coworkers sequenced HCV-p7 in 67 patients with chronic hepatitis C genotype 1 infection (abstract 1245). In those with HCV-1b, a higher number of amino acid mutations within HCV-p7 was associated with virological non-response to IFN-α-based therapy, and impaired response to amantadine appeared to be associated with substitution of L20F in HCV-p7 helix 1.
The importance of adherence
Careful tailoring of IFN treatment is of little value if patients fail to take their medication. Final results from the German Hep-Het acute hepatitis C II multicentre trial clearly show that adherence to therapy is the most important factor for treatment response in acute HCV (abstract 1149). Analysis of data from the total study population of 89 individuals with acute hepatitis C treated with peg-IFN-α2b 1.5 µg/kg for 24 weeks showed an EVR of 82% and an SVR of 71%. However, when only results from 65 individuals who were adherent to therapy and received 80% of the IFN dose within 80% of the scheduled treatment period were analysed, EVR and SVR were 94% and 89% respectively. Johannes Wiegand, from the Hannover Medical School, Germany, and co-workers concluded that the high number of drop-outs in the study underlines the importance of thorough patient selection and close monitoring during therapy.
Successful treatment of hepatitis C is also hampered by adverse events, such as the anaemia associated with RBV that frequently requires that the RBV dose be reduced or prematurely discontinued. Mitchell Shiffmann and colleagues from Virginia Commonwealth University Medical School, Richmond, USA, reported that epoetin-α treatment enabled HCV genotype 1 infected patients to be treated with a high dose of RBV, and thus achieve a better SVR than with standard therapy (abstract 55). Those treated with peg-IFN, high dose RBV and epoetin-α achieved an SVR of 45%, compared with 24% in those treated with standard-dose RBV and epoetin-α, and 27% in those who had standard-dose RBV, without epoetin-α.
Two large Phase III clinical trials of viramidine, the RBV prodrug, have both completed enrollment; however, no data were presented in San Francisco. These studies are expected to be presented at medical meetings in 2006. VISER1 is comparing viramidine to RBV, in combination with peg-IFN-α2b; and VISER2 is comparing viramidine to RBV, in combination with peg-IFN-α2a. After oral administration viramidine is absorbed and taken up by the liver, which converts it to RBV. This reduces its exposure to erythrocytes causing less anaemia and increases its exposure to the liver, the site of HCV replication.
The search for immunoprophylaxis
Promising first clinical data on a novel HCV vaccine E1E2/MF59C.1 were reported by Adrian DiBisceglie and colleagues, from the St Louis University School of Medicine, USA. Significant antibody and lymphocyte proliferation responses were detectable as early as 2 weeks after the third of four vaccinations administered over 48 weeks. The vaccine was relatively well tolerated in the 60 adult study participants who were immunized, with injection site pain (28%), myalgia (25%) and headache (23%) the most commonly reported adverse events.
The use of anti-HCV-neutralizing antibodies is another option under investigation. Multiple antibody infusions administered to chimpanzees acutely infected with HCV modulated the level and length of hepatitis C viraemia and prevented hepatitis, while similar infusions in chronically infected animals changed the rate of HCV replication and ameliorated liver pathology (abstract 202).
In the long term, a vaccine is undoubtedly an important goal in the battle against hepatitis C -as it is for so many life threatening infections. The excellent progress with protease and polymerase inhibitors, reported at AASLD, is very encouraging. Not least is the possibility that, in contrast to HIV, where treatment is needed for life, relatively short courses of these novel agents may be possible. There is now much work to be done in optimizing dosing regimens and, above all, showing that these new agents can be used safely in a wide range of patients with different characteristics and comorbidities.
In the short and medium term, we must continue to rely on the tried and tested peg-IFN-based treatments that are already helping a significant proportion of our patients to eradicate HCV. In clinical trials, the latest advances in tailoring of drug combinations, dosing and duration of treatment are gradually raising response rates, and we must now see if the same can be achieved in everyday practice.
